Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
Clinical trial NCT05653349 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05653349
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-03
- Primary completion
- 2026-10-29
- Enrollment
- 226
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.